Protagonist Therapeutics Inc (NASDAQ:PTGX) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 405,159 shares, a decline of 41.7% from the October 13th total of 694,616 shares. Currently, 3.8% of the company’s shares are sold short. Based on an average daily trading volume, of 101,910 shares, the short-interest ratio is currently 4.0 days.
Protagonist Therapeutics (NASDAQ:PTGX) traded down $1.58 during trading hours on Monday, reaching $17.67. 71,734 shares of the company’s stock were exchanged, compared to its average volume of 84,083. Protagonist Therapeutics has a 52 week low of $8.00 and a 52 week high of $26.36.
Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Monday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.40. The firm had revenue of $8.78 million for the quarter. equities analysts predict that Protagonist Therapeutics will post -3.66 EPS for the current fiscal year.
In related news, insider Richard S. Shames sold 2,017 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $19.00, for a total transaction of $38,323.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Richard S. Shames sold 3,687 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $14.31, for a total transaction of $52,760.97. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,579 shares of company stock valued at $227,374. Company insiders own 15.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System boosted its stake in Protagonist Therapeutics by 8.5% during the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after buying an additional 1,300 shares during the period. Bank of New York Mellon Corp boosted its stake in Protagonist Therapeutics by 5.7% during the second quarter. Bank of New York Mellon Corp now owns 27,626 shares of the company’s stock worth $313,000 after buying an additional 1,478 shares during the period. Geode Capital Management LLC boosted its stake in Protagonist Therapeutics by 1.9% during the first quarter. Geode Capital Management LLC now owns 101,218 shares of the company’s stock worth $1,296,000 after buying an additional 1,850 shares during the period. Wells Fargo & Company MN boosted its stake in Protagonist Therapeutics by 60.8% during the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after buying an additional 3,617 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its stake in Protagonist Therapeutics by 19.5% during the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock worth $264,000 after buying an additional 3,812 shares during the period. 39.68% of the stock is owned by institutional investors.
Several research firms have weighed in on PTGX. Zacks Investment Research raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Saturday, November 11th. ValuEngine downgraded shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 11th. Finally, BMO Capital Markets lowered their price target on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 19th.
ILLEGAL ACTIVITY NOTICE: “Protagonist Therapeutics Inc (NASDAQ:PTGX) Sees Large Drop in Short Interest” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/protagonist-therapeutics-inc-ptgx-sees-significant-decrease-in-short-interest.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.